# CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
Canonical URL: https://biopharmsignal.com/news/CVRX/cvrx-announces-humana-medicare-advantage-coverage-policy-for-barostim-therapy
Ticker: CVRX
Company: CVRx
Source: CVRx
Published: 2026-05-14 12:00 EST
Original Source URL: https://ir.cvrx.com
## Summary

MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Humana has issued

## Article Body
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Humana has issued
## Recent Company News
- 2026-05-27 20:30 EST — [CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/CVRX/cvrx-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: CVRx
- 2026-05-20 20:30 EST — [CVRx to Present at the William Blair 46th Annual Growth Stock Conference](https://biopharmsignal.com/news/CVRX/cvrx-to-present-at-the-william-blair-46th-annual-growth-stock-conference) — Source: CVRx
- 2026-05-14 12:00 EST — [CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy](https://biopharmsignal.com/news/CVRX/cvrx-announces-humana-medicare-advantage-coverage-policy-for-barostim-therapy) — Source: CVRx
- 2026-05-11 20:05 EST — [CVRx Reports First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/CVRX/cvrx-reports-first-quarter-2026-financial-and-operating-results) — Source: CVRx
- 2026-05-04 20:30 EST — [CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population](https://biopharmsignal.com/news/CVRX/cvrx-announces-first-patient-enrollment-in-benefit-hf-a-landmark-heart-failure-trial-evaluating-barostim-in-significantly-expanded-population) — Source: CVRx
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)